CN110997669A - 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途 - Google Patents

取代五元并六元杂环类化合物、其制备方法、药物组合及其用途 Download PDF

Info

Publication number
CN110997669A
CN110997669A CN201880050247.0A CN201880050247A CN110997669A CN 110997669 A CN110997669 A CN 110997669A CN 201880050247 A CN201880050247 A CN 201880050247A CN 110997669 A CN110997669 A CN 110997669A
Authority
CN
China
Prior art keywords
hydrogen
alkyl
substituted
amino
following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880050247.0A
Other languages
English (en)
Other versions
CN110997669B (zh
Inventor
邓贤明
黄伟
孙细欢
张婷
何志祥
刘琰
吴昕瑞
张保锭
李小阳
张婧芳
陈云
李莉
徐庆妍
胡志钰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen University
Original Assignee
Xiamen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen University filed Critical Xiamen University
Priority to CN202210486406.XA priority Critical patent/CN115057855B/zh
Publication of CN110997669A publication Critical patent/CN110997669A/zh
Application granted granted Critical
Publication of CN110997669B publication Critical patent/CN110997669B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

一类具有PIKfyve激酶选择性抑制活性的取代五元并六元杂环化合物及其药学上可接受的盐或药学上可接受的溶剂合物，其制备方法、包含该化合物的药物组合物，以及这些化合物在制备用于预防或治疗与生物体内PIKfyve相关疾病的药物中的用途，尤其是在制备用于预防或治疗肿瘤生长与转移的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN201880050247.0A 2017-08-04 2018-08-03 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途 Active CN110997669B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210486406.XA CN115057855B (zh) 2017-08-04 2018-08-03 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017106588947 2017-08-04
CN201710658894.7A CN109384782A (zh) 2017-08-04 2017-08-04 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
PCT/CN2018/098457 WO2019024908A1 (zh) 2017-08-04 2018-08-03 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210486406.XA Division CN115057855B (zh) 2017-08-04 2018-08-03 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途

Publications (2)

Publication Number Publication Date
CN110997669A true CN110997669A (zh) 2020-04-10
CN110997669B CN110997669B (zh) 2022-12-27

Family

ID=65232294

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201710658894.7A Pending CN109384782A (zh) 2017-08-04 2017-08-04 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
CN201880050247.0A Active CN110997669B (zh) 2017-08-04 2018-08-03 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
CN202210486406.XA Active CN115057855B (zh) 2017-08-04 2018-08-03 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710658894.7A Pending CN109384782A (zh) 2017-08-04 2017-08-04 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210486406.XA Active CN115057855B (zh) 2017-08-04 2018-08-03 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途

Country Status (9)

Country Link
US (1) US11352354B2 (zh)
EP (1) EP3663293A4 (zh)
JP (2) JP7050093B2 (zh)
CN (3) CN109384782A (zh)
AU (1) AU2018309245B2 (zh)
CA (1) CA3071900A1 (zh)
IL (1) IL272446A (zh)
TW (1) TW201910329A (zh)
WO (1) WO2019024908A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
CN111825674A (zh) * 2019-04-22 2020-10-27 上海仕谱生物科技有限公司 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
EP4028133A1 (en) 2019-09-13 2022-07-20 The United States of America, as represented by The Secretary, Department of Health and Human Services Receptor tyrosine kinase inhibitors for treatment of protein kinase modulation-responsive disease or disorder
US11814388B1 (en) 2020-08-28 2023-11-14 Ferris State University Substituted pyrrolo[2,3-d]pyrimidines and pyrazolo[3,4-d]pyrimidines as inhibitors for multi-resistant cancers
CN118019744A (zh) * 2021-09-30 2024-05-10 韩美药品株式会社 PIKfyve激酶抑制剂
CN114149409B (zh) * 2021-11-16 2024-03-22 中国药科大学 一种具有蛋白激酶抑制活性的（杂）芳基酰胺类化合物
US11814384B2 (en) 2022-02-03 2023-11-14 Kinnate Biopharma Inc. Inhibtors of Raf kinases
CN117045659B (zh) * 2023-08-21 2024-05-10 浙江大学 一种7-氮杂吲哚-6-胺类clip1-ltk融合蛋白调控剂的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1426398A (zh) * 2000-04-27 2003-06-25 山之内制药株式会社 稠合杂芳基衍生物
WO2005014599A1 (en) * 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
CN101351467A (zh) * 2005-11-30 2009-01-21 诺瓦提斯公司 作为EphB和VEGFR2激酶抑制剂的3-(取代的氨基)-吡唑并[3,4-d]嘧啶类物质
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
WO2016210330A1 (en) * 2015-06-26 2016-12-29 Kadmon Corporation, Llc Glucose uptake inhibitors
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5280862B2 (ja) * 2006-01-23 2013-09-04 アムジエン・インコーポレーテツド オーロラキナーゼ調節剤および使用方法
US20090149458A1 (en) * 2007-11-27 2009-06-11 Wyeth PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
CN104177363B (zh) * 2013-05-24 2018-06-05 江苏先声药业有限公司 双环杂环胺类Hedgehog信号通路抑制剂
WO2016118709A1 (en) * 2015-01-23 2016-07-28 Lam Therapeutics, Inc. Anti-viral compositions containing pikfyve inhibitors and use thereof
CN106188060A (zh) * 2015-04-29 2016-12-07 厦门大学 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用
CA2988461A1 (en) * 2015-06-26 2016-12-29 Dana-Farber Cancer Institute, Inc. Fused bicyclic pyrimidine derivatives and uses thereof
WO2017004133A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN107531725B (zh) * 2015-08-13 2021-03-19 北京韩美药品有限公司 Irak4抑制剂及其应用
AU2016366810A1 (en) 2015-12-09 2018-06-28 Jawaharlal Nehru Centre For Advanced Scientific Research Method for modulating autophagy and applications thereof
CN109180677A (zh) * 2017-06-30 2019-01-11 厦门大学 取代芳基醚类化合物、其制备方法、药用组合物及其应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1426398A (zh) * 2000-04-27 2003-06-25 山之内制药株式会社 稠合杂芳基衍生物
WO2005014599A1 (en) * 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
CN101351467A (zh) * 2005-11-30 2009-01-21 诺瓦提斯公司 作为EphB和VEGFR2激酶抑制剂的3-(取代的氨基)-吡唑并[3,4-d]嘧啶类物质
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
WO2016210330A1 (en) * 2015-06-26 2016-12-29 Kadmon Corporation, Llc Glucose uptake inhibitors
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GEORG MARTINY-BARON ET AL.: "The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis", 《ANGIOGENESIS》 *
NATHALIE BOULOC ET AL.: "Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells", 《BIOORG. MED. CHEM. LETT.》 *
WEI HUANG ET AL.: "Discovery and Identification of Small Molecules as Methuosis Inducers with in Vivo Antitumor Activities", 《J.MED.CHEM》 *
ZECHENG CHEN ET AL.: "Synthesis and SAR of Novel 4-Morpholinopyrrolopyrimidine Derivatives as Potent Phosphatidylinositol 3-Kinase Inhibitors", 《J. MED. CHEM.》 *

Also Published As

Publication number Publication date
WO2019024908A1 (zh) 2019-02-07
CN109384782A (zh) 2019-02-26
AU2018309245B2 (en) 2021-03-04
JP2020529968A (ja) 2020-10-15
AU2018309245A1 (en) 2020-03-19
EP3663293A4 (en) 2021-04-21
CN110997669B (zh) 2022-12-27
US11352354B2 (en) 2022-06-07
EP3663293A1 (en) 2020-06-10
TW201910329A (zh) 2019-03-16
CN115057855B (zh) 2024-04-26
CA3071900A1 (en) 2019-02-07
CN115057855A (zh) 2022-09-16
IL272446A (en) 2020-03-31
US20200165246A1 (en) 2020-05-28
JP2021176847A (ja) 2021-11-11
JP7050093B2 (ja) 2022-04-07

Similar Documents

Publication Publication Date Title
CN110997669B (zh) 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
JP7373992B2 (ja) 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法
CN107151250B (zh) 嘧啶类七元环化合物、其制备方法、药用组合物及其应用
EP3626718B1 (en) Five-membered-fused-six-membered aza-aromatic ring compound, preparation method thereof, pharmaceutical composition and application thereof
JP6963598B2 (ja) チエノピリミジン系化合物、その製造方法、医薬組成物およびその応用
JP7439018B2 (ja) 置換アリールエーテル系化合物、その調製方法、医薬組成物およびその応用
JP2018516278A (ja) プテリジノン誘導体のｅｇｆｒ阻害剤としての使用
JP2002508007A (ja) Ｍｄｒモジュレーターとしてのイミダゾール誘導体
TWI780077B (zh) 噻吩並嘧啶類化合物、其製備方法、藥用組合物及其應用
CN111295387B (zh) 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用
CN109111439B (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
CN111875583B (zh) 三氮唑衍生物及其制备方法和用途
CN115916759A (zh) 取代喹唑啉类化合物、其制备方法、药物组合及应用
NZ744393B2 (en) Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof
JP2005008624A (ja) テトラハイドロキノリン骨格を有するスルホンアミド誘導体およびその塩

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant